Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
2.8 GBX 0.35 ( 14.29%)
Last update at 2026-10-27T17:05:00Z
VOLUME
4244889
Market Cap
16.87M

Momentum Score

…

Eden Research plc, together with its subsidiaries, engages in the development and sale of biopesticides in Europe and the United Kingdom. The company offers foliar disease and insect control, open field and greenhouses, soil pests, post-harvest shelf-life extension, and seed treatments under the Mevalone and Cedroz brands for crop protection applications. It also provides consume products, such as head-lice treatment, deodorants, odour neutralizer, and fragrances, as well as food flavourings and active ingredients; and animal health products comprising companion animal, bio-control, parasite treatments, and insect sprays. Eden Research plc was incorporated in 1995 and is headquartered in Abingdon, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.50
Low
2.90
High
52 Week Price Range
1.96
Low
5.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Eden Research plc is a UK-listed company that develops plant-health and crop-protection technologies based on botanical and formulation expertise. Long-term growth could be supported by regulatory shifts toward sustainable crop inputs and by wider adoption or licensing of its technologies. Investors may find the company attractive for niche technology exposure to the sustainable agriculture transition.

Principal risks include small size and limited revenues, dependence on R&D and regulatory approvals, competition from larger agrochemical firms, and funding and execution risk common to small-cap developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.45
Dividend Yield
-
Revenue TTM
3.62M
Revenue Per Share
0.01
Gross Profit TTM
1.87M
Debt / Equity
0.01
ROE
-20.10%
Net Debt
-3.51M
ROCE
-18.24%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -2.18M -6.92M -2.57M -3.40M -2.55M
Minority interest 0.01M -0.00M 0.01M -0.01M 0.02M
Net income -1.91M -6.49M -2.24M -2.78M -2.26M
Selling general administrative 3.51M 3.00M 2.75M 2.69M 2.20M
Selling and marketing expenses - 0.24M - - -
Gross profit 1.87M 1.77M 0.83M 0.56M 0.63M
Reconciled depreciation 0.58M 0.63M 0.69M 0.59M 0.62M
Ebit -2.17M -6.87M -2.57M -3.21M -2.24M
Ebitda -1.59M -6.24M -1.86M -2.77M -1.60M
Depreciation and amortization 0.58M 0.63M 0.71M 0.43M 0.63M
Operating income -2.19M -1.87M -2.57M -3.21M -2.24M
Other operating expenses 6.49M 5.06M 4.39M 4.44M 3.60M
Interest expense 0.01M 0.02M 0.02M 0.03M 0.02M
Tax provision -0.27M -0.43M -0.32M -0.62M -0.29M
Interest income 0.11M 0.03M 0.00M 0.00M 0.01M
Net interest income 0.10M 0.02M -0.02M -0.03M -0.02M
Income tax expense -0.27M -0.43M -0.32M -0.62M -0.29M
Total revenue 4.30M 3.19M 1.83M 1.23M 1.37M
Total operating expenses 4.06M 3.63M 3.40M 3.77M 2.87M
Cost of revenue 2.43M 1.43M 1.00M 0.67M 0.74M
Total other income expense net 0.01M -5.05M -0.00M -0.19M -0.31M
Net income from continuing ops -1.91M -6.49M -2.24M -2.78M -2.26M
Net income applicable to common shares - - - -2.79M -2.27M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 15.41M 16.59M 12.91M 15.03M 16.92M
Intangible assets 6.89M 4.71M 8.45M 7.92M 6.73M
Other current assets 0.83M 0.70M - 1.79M 1.68M
Total liab 3.57M 3.05M 2.17M 2.20M 2.00M
Total stockholder equity 11.82M 13.52M 10.72M 12.80M 14.91M
Deferred long term liab - - - 5.44M 4.13M
Other current liab 0.62M 0.69M 0.66M 0.56M 0.66M
Common stock 5.33M 5.33M 3.81M 3.80M 3.80M
Capital stock 5.33M 5.33M 3.81M 3.80M 3.80M
Retained earnings -0.72M 1.01M -43.31M -41.46M -38.84M
Other liab - - - 0.09M 0.13M
Other assets - - - 5.44M 4.13M
Cash 3.67M 7.41M 1.99M 3.83M 7.29M
Total current liabilities 3.51M 2.96M 1.95M 1.81M 1.54M
Current deferred revenue - 0.00M - - -
Net debt -3.51M -7.18M -1.64M -3.43M -6.87M
Short term debt 0.22M 0.29M 0.14M 0.10M 0.08M
Short long term debt total 0.17M 0.23M 0.36M 0.40M 0.42M
Other stockholder equity 6.41M 6.41M 50.22M 50.46M 49.95M
Property plant equipment - - - 0.61M 0.58M
Total current assets 7.90M 11.14M 3.60M 6.14M 9.19M
Net tangible assets - - - 10.32M 12.31M
Net receivables 2.86M 2.06M 0.32M 1.77M 1.49M
Inventory 0.53M 0.96M 0.63M 0.52M 0.22M
Accounts payable 2.56M 1.93M 1.15M 1.15M 0.79M
Accumulated other comprehensive income 0.79M 0.76M - - -0.07M
Common stock total equity - - - - 3.80M
Non currrent assets other - 4.71M 0.33M 0.36M 0.42M
Non current assets total 7.51M 5.45M 9.31M 8.89M 7.73M
Capital lease obligations 0.17M 0.23M 0.36M 0.40M 0.42M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -2.48M -1.72M -1.05M -1.73M -1.90M
Change to liabilities - - - 0.16M 0.11M
Total cashflows from investing activities -2.48M -1.72M - -1.73M -1.90M
Net borrowings - - - -0.09M -0.04M
Total cash from financing activities -0.16M 8.90M -0.15M -0.09M 9.71M
Net income -1.90M -6.49M -2.24M -2.78M -2.26M
Change in cash -3.74M 5.42M -1.83M -3.46M 6.78M
Begin period cash flow 7.41M 1.99M 3.83M 7.29M 0.50M
End period cash flow 3.67M 7.41M 1.99M 3.83M 7.29M
Total cash from operating activities -1.01M -1.70M -0.68M -1.62M -1.02M
Issuance of capital stock 0.00M 9.06M - 0.00M 10.39M
Depreciation 0.58M 0.63M 0.69M 0.59M 0.62M
Other cashflows from investing activities -2.43M -1.62M - 0.00M 0.01M
Change to inventory 0.43M -0.34M -0.18M -0.30M -0.16M
Change to account receivables -0.66M -1.79M - 0.51M 0.24M
Other cashflows from financing activities -0.01M -0.02M -1.05M -1.73M -0.68M
Change to netincome - - - 0.20M 0.44M
Capital expenditures 2.59M 0.10M 1.05M 1.73M 1.90M
Change in working capital 0.34M -1.13M -0.06M 0.38M 0.19M
Stock based compensation 0.20M 0.24M 0.15M 0.64M 0.12M
Other non cash items -0.24M 5.06M 0.79M 0.12M 0.02M
Free cash flow -3.60M -1.80M -1.74M -3.34M -2.92M

Peer Comparison*

Sector: Basic Materials Industry: Agricultural Inputs

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EDEN
Eden Research plc
0.35
14.29%
2.80 - - 4.67 1.59 4.31 -4.90
OGN
Origin Enterprises Plc
-3.90
1.16%
331.10 12.13 8.08 0.21 1.21 0.40 6.99
WYN
Wynnstay Group Plc
-2.00
0.59%
338.00 35.75 11.31 0.14 0.60 0.12 6.05
EML
Emmerson PLC
-0.03
2.27%
1.07 - - - 32.37 - -5.30
KRPZ
Kropz Plc
-0.42
99.01%
0.00 1.30 - 0.53 0.38 2.38 3.94

Profile*

Eden Research plc

Eden Research plc, together with its subsidiaries, engages in the development and sale of biopesticides in Europe and the United Kingdom. The company offers foliar disease and insect control, open field and greenhouses, soil pests, post-harvest shelf-life extension, and seed treatments under the Mevalone and Cedroz brands for crop protection applications. It also provides consume products, such as head-lice treatment, deodorants, odour neutralizer, and fragrances, as well as food flavourings and active ingredients; and animal health products comprising companion animal, bio-control, parasite treatments, and insect sprays. Eden Research plc was incorporated in 1995 and is headquartered in Abingdon, the United Kingdom.

67C Innovation Drive, Abingdon, United Kingdom, OX14 4RQ

44 12 8535 9555

23

Name Title Year Born
Mr. Sean M. Smith CEO & Exec. Director NA
Mr. Alexander John Abrey CFO, Sec. & Exec. Director NA
Dr. Aoife Dillon Global Head of Biology & Devel. NA
Mr. Sean Michael Smith CEO & Executive Director 1967
Mr. Alexander John Abrey CFO, Secretary & Executive Director 1979

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…